Company sells 390,167 common shares to Baxalta at $25.63 per share
By Tali Rackner
Norfolk, Va., Sept. 14 – Coherus BioSciences, Inc. completed a $10 million stock purchase agreement on Sept. 10, according to an 8-K filing with the Securities and Exchange Commission.
The company sold 390,167 common shares to Baxalta Inc., Baxalta US Inc. and Baxalta GmbH at $25.63 per share. The price per share is identical to the Sept. 9 closing share price.
The clinical biologics platform company is based in Redwood City, Calif.
| Issuer: | Coherus BioSciences, Inc.
|
| Issue: | Common stock
|
| Amount: | $10 million
|
| Shares: | 390,167
|
| Price: | $25.63
|
| Warrants: | No
|
| Investors: | Baxalta Inc., Baxalta US Inc. and Baxalta GmbH
|
| Pricing date: | Sept. 9
|
| Closing date: | Sept. 10
|
| Stock symbol: | Nasdaq: CHRS
|
| Stock price: | $25.63 at close Sept. 9
|
| Market capitalization: | $1.01 billion
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
